Publikationen, an denen er mitarbeitet Alberto Cordero Fort (66)

2024

  1. Applicability of the Zwolle score for selection of very high-risk ST-elevation myocardial infarction patients treated with primary angioplasty

    Angiology, Vol. 75, Núm. 2, pp. 175-181

  2. The CNIC-polypill (acetylsalicylic acid, atorvastatin, and ramipril), an effective and cost-saving secondary prevention strategy compared with other therapeutic options in patients with ischaemic heart disease

    European Heart Journal Open, Vol. 4, Núm. 2

2023

  1. Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial

    International Journal of Cardiology, Vol. 391

  2. Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials

    The American journal of cardiology, Vol. 205, pp. 321-324

  3. Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 5, pp. 583-593

  4. Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase

    Primary Care Diabetes, Vol. 17, Núm. 4, pp. 366-372

  5. Differential prognosis of patients that are candidates for standard, short or prolonged dual antiplatelet treatment discharged after an acute coronary syndrome

    Thrombosis Research, Vol. 224, pp. 46-51

  6. Effect of dapagliflozin on COVID-19 infection and risk of hospitalization

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2335-2342

  7. Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis

    Journal of cardiovascular pharmacology, Vol. 81, Núm. 1, pp. 70-75

  8. Remnant cholesterol in patients admitted for acute coronary syndromes

    European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 340-348

  9. The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events

    Journal of Clinical Lipidology, Vol. 17, Núm. 5, pp. 602-611

2022

  1. Clinical and therapeutic characterization of the ischemic cardiopathy in Spain. Importance of cardiac rehabilitation programs

    Medicina Clinica Practica, Vol. 5, Núm. 3

  2. Early angiography in elderly patients with non-ST-segment elevation acute coronary syndrome: The cardio CHUS-HUSJ registry

    International Journal of Cardiology, Vol. 351, pp. 8-14

  3. Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 12

  4. Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 245-252

  5. Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril-Valsartan in Clinical Trials

    American journal of therapeutics, Vol. 29, Núm. 5, pp. e572-e575

  6. Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry

    Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529

  7. Should PRECISE-DAPT be included for long-term prognostic stratification of diabetic patients with NSTEACS?

    Acta Diabetologica, Vol. 59, Núm. 2, pp. 163-170

  8. The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study

    International Journal of Cardiology, Vol. 361, pp. 116-123

2021

  1. Direct Oral Anticoagulants Versus Vitamin-K Antagonist After PCIs in Patients With AF: A Meta-analysis of Cardiac Ischemic Events

    Journal of cardiovascular pharmacology, Vol. 77, Núm. 2, pp. 164-169